These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9109740)

  • 41. Single-blind, placebo-controlled pilot study of pregabalin for ataxia in cortical cerebellar atrophy.
    Gazulla J; Benavente I
    Acta Neurol Scand; 2007 Oct; 116(4):235-8. PubMed ID: 17824901
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose piracetam is effective on cerebellar ataxia in patient with cerebellar cortical atrophy.
    Vural M; Ozekmekçi S; Apaydin H; Altinel A
    Mov Disord; 2003 Apr; 18(4):457-9. PubMed ID: 12671958
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease.
    Harrell LE; Jope RS; Falgout J; Callaway R; Avery C; Spiers M; Leli D; Morere D; Halsey JH
    J Am Geriatr Soc; 1990 Feb; 38(2):113-22. PubMed ID: 2405043
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease.
    Thal LJ; Ferguson JM; Mintzer J; Raskin A; Targum SD
    Neurology; 1999 Apr; 52(6):1146-52. PubMed ID: 10214735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Latanoprost and physostigmine have mostly additive ocular hypotensive effects in human eyes.
    Lindén C; Alm A
    Arch Ophthalmol; 1997 Jul; 115(7):857-61. PubMed ID: 9230825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Phosphatidylcholine in the treatment of degenerative spinocerebellar ataxic syndromes. Long-term study of 6 patients].
    De Luca G; Sottile G; Nastasi G; Casaceli A
    Riv Neurol; 1983; 53(6):392-9. PubMed ID: 6669885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral physostigmine and lecithin improve memory in Alzheimer disease.
    Thal LJ; Fuld PA; Masur DM; Sharpless NS
    Ann Neurol; 1983 May; 13(5):491-6. PubMed ID: 6347034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of buspirone for the treatment of cerebellar ataxia in an older individual.
    Holroyd-Leduc JM; Liu BA; Maki BE; Zecevic A; Herrmann N; Black SE
    Can J Clin Pharmacol; 2005; 12(3):e218-21. PubMed ID: 16278493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cortisol responses to cholinergic drugs in Alzheimer's disease.
    Kumar V; Smith RC; Sherman KA; Ashford W; Murphy J; Giacobini E; Colliver J
    Int J Clin Pharmacol Ther Toxicol; 1988 Oct; 26(10):471-6. PubMed ID: 3069749
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases.
    Miyai I; Ito M; Hattori N; Mihara M; Hatakenaka M; Yagura H; Sobue G; Nishizawa M;
    Neurorehabil Neural Repair; 2012 Jun; 26(5):515-22. PubMed ID: 22140200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Placebo response in degenerative cerebellar ataxias: a descriptive review of randomized, placebo-controlled trials.
    Choi JH; Shin C; Kim HJ; Jeon B
    J Neurol; 2022 Jan; 269(1):62-71. PubMed ID: 33219422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Memory decline in the aged: treatment with lecithin and physostigmine.
    Drachman DA; Glosser G; Fleming P; Longenecker G
    Neurology; 1982 Sep; 32(9):944-50. PubMed ID: 6287359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effect of buspirone, a serotonergic 5-HT-1A agonist in cerebellar ataxia: a pilot study. Preliminary communication].
    Trouillas P; Xie J; Getenet JC; Adeleine P; Nighoghossian N; Honnorat J; Riche G; Derex L
    Rev Neurol (Paris); 1995 Dec; 151(12):708-13. PubMed ID: 8787101
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.
    Asthana S; Raffaele KC; Berardi A; Greig NH; Haxby JV; Schapiro MB; Soncrant TT
    Alzheimer Dis Assoc Disord; 1995; 9(4):223-32. PubMed ID: 8749612
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.
    Christie JE; Shering A; Ferguson J; Glen AI
    Br J Psychiatry; 1981 Jan; 138():46-50. PubMed ID: 7023592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis.
    Monaca-Charley C; Stojkovic T; Duhamel A; De Seze J; Ferriby D; Vermersch P
    J Neurol; 2003 Oct; 250(10):1190-4. PubMed ID: 14586600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Buspirone in the treatment of cerebellar ataxia].
    Svetel M; Vojvodić N; Filipović SR; Dragasević N; Sternić N; Kostić VS
    Srp Arh Celok Lek; 1999; 127(9-10):312-5. PubMed ID: 10649900
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low dose choline chloride in cerebellar degeneration.
    Austin CA; Mundy KI; Dorey S
    J Neurol Neurosurg Psychiatry; 1984 Sep; 47(9):1038-40. PubMed ID: 6481372
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
    Davis KL; Mohs RC
    Am J Psychiatry; 1982 Nov; 139(11):1421-4. PubMed ID: 6753611
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term administration of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.